pharmacogenomics and personalized medicines
DESCRIPTION
Pharmacogenomics and personalized medicines. Jean-Marie Boeynaems [email protected]. OUTLINE. Definitions : SNP, omics Personalized choice of the medicinal product Personalized dosage of the medicinal product Problems and first achievements Individualized treatment of cancer - PowerPoint PPT PresentationTRANSCRIPT
![Page 2: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/2.jpg)
OUTLINE
• Definitions : SNP, omics• Personalized choice of the medicinal product• Personalized dosage of the medicinal product• Problems and first achievements• Individualized treatment of cancer• Genome-wide association studies• Technological evolution of sequencing : • « The 1,000 $ genome challenge »• Generalization of genome sequencing : • ethical, legal and practical issues
![Page 3: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/3.jpg)
A representative sample of the slides that will be presented and discussed during the course is
displayed hereafter.
![Page 4: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/4.jpg)
Different types of SNP
• Outside genes : no impact
• In the genes coding sequence :
• change of base but not of amino acid (cf redundancy of genetic code : GCA et GCC both code for alanine)
• change of amino acid : more or less impressive
modification of function (loss or gain)
• In the promoter region : or transcription of the gene and protein expression
• In the mRNA 3’-untranslated region : (or ) sensitivity to miRNA (that inhibit translation and destabilize mRNA).
![Page 5: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/5.jpg)
Ome, Omics
• Genomics: all the genes• pharmacogenomics : choice of personalized medicine • nutrigenomics : choice of best diet• toxicogenomics : prediction of toxicity
• Epigenomics: all epigenetic changes in genome• Transcriptomics: all the mRNAs microarrays• Proteomics : all the proteins• Interactomics : all interactions between all proteins• Metabolomics (or metabonomics) : all metabolites • …
![Page 6: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/6.jpg)
« Personalized medicines »based on pharmacogenomics
• Identification of genes conferring to individuals who carry them a better sensitivity to the therapeutic action of a medicine or a better tolerance (drug metabolizing enzymes, disease susceptibility factors)
• Genotyping before inclusion in a clinical trial statistical power and cost
• Simultaneous marketing of a medicinal product and availability of a genetic test to identify patients to treat
• Restriction of the market but higher price since efficacy is optimized (or adverse effects decreased) .
![Page 7: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/7.jpg)
From personalized medicine to precision medicine
• Some are skeptical that medicine will really be personalized, while others say that physicians have always adapted treatment to their individual patients.
• Precision medicine implies that diseases are defined by underlying molecular mechanisms rather than traditional signs and symptoms.
Lancet 378 : 1678, 2011
Toward precision medicine
US National Research Council, nov 2011
![Page 8: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/8.jpg)
![Page 9: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/9.jpg)
Cancer Pharmacogenomics and Tumor and Germline Genomes
Wang L et al. N Engl J Med 2011;364:1144-1153.
![Page 10: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/10.jpg)
Anticancer drugs approved by the Food and Drug Administration with labeling regarding pharmacogenomic biomarkers
Wang L et al. N Engl J Med 2011;364:1144-1153.
![Page 11: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/11.jpg)
Lebrikizumab treatmentin asthma : efficacy related to serum periostin
Corren et al NEJM 2011
Lebrikizumab is a monoclonal
antibody that neutralizes IL-13. IL-13 induces bronchial epithelial cellsto secrete periostin. Patients with high serum periostin respond better.
![Page 12: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/12.jpg)
![Page 13: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/13.jpg)
DNA cleaved in fragmentsFragments fixed on beads (excess)PCR amplification in emulsion (1 bead/droplet)Transfer to multi-well (pL) slide(1 bead/well)Addition of smaller beads covered with enzymes involved in sequencing
![Page 14: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/14.jpg)
Elongation of fragmentsSequential injection of nucleotidesIf the nucleotide is incorporated, generation of light detected by a
camera
![Page 15: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/15.jpg)
Cost of genome sequencing
• Genome of C Venter : 100x106 $• Genome of J Watson : < 1.5x106 $• X Prize Foundation challenge : 10,000 $• Race for $ 1,000 genome : 1,000 $• Complete Genomics in 2009 : 4,400 $• Cost of the detection of a single mutation by
Belgian genetics laboratories : 300
![Page 16: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/16.jpg)
![Page 17: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/17.jpg)
Report freely accessibleon www.deloitte.com
![Page 18: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/18.jpg)
![Page 19: Pharmacogenomics and personalized medicines](https://reader038.vdocuments.net/reader038/viewer/2022103006/56813b64550346895da4652e/html5/thumbnails/19.jpg)
Take home messages
• The business model of biopharma is changing and can now include personalized medicines.
• The major difficulty is to identify SNPs with a strong impact on treatment choice/dosage.
• Personalized medicines are making progress especially in cancer treatment, but also in asthma.
• A key element is the astounding evolution of technology with a dramatic decrease in the cost of sequencing.